Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B

• Published in: JHEP reports Vol. 3; no. 3; p. 100290
• Main Authors: Papatheodoridis, George V., Dalekos, George N., Idilman, Ramazan, Sypsa, Vana, Van Boemmel, Florian, Buti, Maria, Calleja, Jose Luis, Goulis, John, Manolakopoulos, Spilios, Loglio, Alessandro, Papatheodoridi, Margarita, Gatselis, Nikolaos, Veelken, Rhea, Lopez-Gomez, Marta, Hansen, Bettina E., Savvidou, Savvoula, Kourikou, Anastasia, Vlachogiannakos, John, Galanis, Kostas, Yurdaydin, Cihan, Esteban, Rafael, Janssen, Harry L.A., Berg, Thomas, Lampertico, Pietro
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.2021; Elsevier
• Subjects: Cirrhosis; Entecavir; Prediction; Tenofovir; ETV; Entecavir; Prediction; ALT; AUROC; HCC; HR; Tenofovir; Cirrhosis; NA; NPV; ULN; PPV; TDF; CHB; ALT, alanine aminotransferase; AUROC, area under receiver operating characteristic; HR, hazard ratio; CHB, chronic hepatitis B; NA, nucleos(t)ide analogue; ETV, entecavir; ULN, upper limit of normal; NPV, negative predictive value; PPV, positive predictive value; TDF, tenofovir disoproxil fumarate; HCC, hepatocellular carcinoma
• ISSN: 2589-5559; 2589-5559
• DOI: 10.1016/j.jhepr.2021.100290

Recently, several risk scores for prediction of hepatocellular carcinoma (HCC) were developed in cohorts of treated Asian patients with chronic hepatitis B (CHB), but they have not been assessed in non-Asian patients. We evaluated the predictability and comparative utility of our PAGE-B and recent Asian HCC risk scores in nucleos(t)ide analogue (NA)-treated adult Caucasian patients with CHB, with or without well-documented compensated cirrhosis but not previous diagnosis of HCC. We included 1,951 patients treated with entecavir/tenofovir and followed up for a median of 7.6 years. The c-statistic was used to estimate the predictability of PAGE-B, HCC-Rescue, CAMD, mPAGE-B, and AASL score for HCC development within 5 or 10 years. The low- and high-risk group cut-offs were used for estimation of negative (NPV) and positive predictive values (PPV), respectively. HCC developed in 103/1,951 (5.3%) patients during the first 5 years and in another 39/1,428 (2.7%) patients between years 5 and 10. The 3-, 5-, and 10-year cumulative HCC rates were 3.3%, 5.9%, and 9.6%, respectively. All scores offered good 5- and 10-year HCC prediction (c-statistic: 0.78–0.82). NPVs were always >99% (99.3–100%), whereas PPV ranged between 13% and 24%. In NA-treated Caucasian patients with CHB including compensated cirrhosis, HCC risk scores developed in NA-treated Asian patients offer good 5- and 10-year HCC predictability, similar to that of PAGE-B. PAGE-B and mPAGE-B scores are simpler in clinical practice, as they do not require an accurate diagnosis of cirrhosis, but the addition of albumin in mPAGE-B score does not seem to offer an advantage in patients with well compensated liver disease. Several risk scores for prediction of hepatocellular carcinoma (HCC) were recently developed in cohorts of treated Asian patients with chronic hepatitis B (CHB). In Caucasian patients with CHB treated with oral antivirals, newer Asian HCC risk scores offer good 5- and 10-year HCC predictability, similar to that of PAGE-B. For clinical practice, PAGE-B and mPAGE-B scores are simpler, as they do not require an accurate diagnosis of cirrhosis. [Display omitted] •In treated Caucasian patients with chronic hepatitis B, newer Asian hepatocellular carcinoma risk scores offer good 5- and 10-year predictability, similar to that of PAGE-B.•PAGE-B and mPAGE-B scores are simpler in clinical practice, as they do not require an accurate diagnosis of cirrhosis.•The addition of albumin in mPAGE-B does not seem to offer an advantage in patients with well-compensated liver disease.